Wednesday 3 May, 6:00-7:00pm
This event has now taken place – you can see a recording of the webinar on National Eczema Society’s Facebook page.
This free webinar features two informative talks from dermatology experts at the forefront of eczema research and practice. We will explore the new systemic treatments for people with more severe eczema and how they work, including biologic and JAK-inhibitor medicines. We will also look at how research is helping us understand more about how systemic eczema treatments work, and highlight a new research study called BEACON. This study is looking to compare the effectiveness of different eczema treatments. National Eczema Society and St John’s Derm Academy are pleased to collaborate to bring you this free webinar. There will be time after the talks for you to ask questions of the speakers and panel.
The webinar will be livestreamed via Facebook and the recording will remain available to watch afterwards – see here. To able to participate in the webinar, you would need to register in advance.
6:00pm Welcome and overview of the evening
Professor Catherine Smith
6:05pm What are the new systemic treatments for severe eczema and how do we know how good they really are?
Dr Andrew Pink
6:25pm Understanding how systemic eczema treatments work
Dr Satveer Mahil
6:45pm Question and answer session with a panel including webinar speakers, plus Professor Catherine Smith and Andrew Proctor, Chief Executive of National Eczema Society. Participants are encouraged to ask questions on the topics being presented, as well as other areas of eczema care.
7:00pm Close
Webinar speakers and panel
Professor Catherine Smith
Consultant Dermatologist, St John’s Institute of Dermatology
Guy’s and St Thomas’ NHS Foundation Trust, London
Professor Smith is Consultant Dermatologist and Professor of Dermatology and Therapeutics at St John’s Institute of Dermatology, Kings College London and Guys and St Thomas’ Hospital. She is lead clinician in national specialised services for adults with severe eczema. Her clinical and research interests focus on inflammatory skin disease and translational medicine, extending from biomarker discovery through to interventional studies (phase II-IV), and involve major national and international collaboration. These include BIOMAP, a European-wide consortium focussed on identifying clinically relevant biomarkers in atopic eczema and psoriasis https://biomap-imi.eu/ and BEACON – a UK wide platform trial of systemic interventions in adult eczema https://www.beacontrial.org/.
Dr Andrew Pink
Consultant Dermatologist and Director of Adult Clinical Trials Unit
St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust
Honorary Senior Clinical Lecturer, King’s College London
Dr Pink is a consultant dermatologist and the Director of the adult Clinical Trials Unit at St John’s Institute of Dermatology, Guy’s and St Thomas’ Hospitals, London. He is an Honorary Senior Clinical Lecturer at King’s College London, ex-Honorary Secretary of the St John’s Dermatological Society, a member of the International Psoriasis Council, Chair of the Annual UK Dermatology Course for Consultants and regularly acts as a NICE clinical expert. His clinical and academic interests focus on inflammatory skin disease and translational medicine, primarily in eczema and psoriasis. Andrew has helped to develop a national multi-disciplinary eczema service and a very active trials unit (phase II-IV) at St. John’s. He has acted as CI on multiple trials examining novel therapies emerging in psoriasis and eczema and is the Chief Investigator for the BEACON trial, a large UK platform trial designed to assess the comparative effectiveness of systemic therapies for moderate to severe eczema in adults.
Dr Satveer Mahil
Consultant Dermatologist
St John’s Institute of Dermatology
Guy’s and St Thomas’ NHS Foundation Trust
Dr Mahil is a Consultant Dermatologist at Guy’s and St Thomas’ Hospital. She qualified from Cambridge University and completed integrated academic training (NIHR Academic Clinical Fellowship and NIHR Clinical Lectureship) in dermatology at St John’s. She completed a MRC-funded PhD in 2017, during which she used genetic information to gain novel insights into the mechanistic basis of different forms of psoriasis, and define new therapeutic targets.
Alongside her clinical and education work at St John’s, she continues to conduct translational research, which is focused on optimising outcomes for individuals with inflammatory skin diseases.
Andrew Proctor
Chief Executive of National Eczema Society
Andrew joined National Eczema Society as Chief Executive in March 2018. He has worked in the voluntary sector for over 15 years, including spells with Asthma UK, Alzheimer’s Society and Action Medical Research. He believes passionately in people having the right information and advice to make informed choices about their health, and in supporting people to self-manage their health conditions effectively. Andrew has a particular interest in digital, which he sees as playing an increasingly important role in healthcare and in helping National Eczema Society reach more people affected by eczema. He is inspired by the Society’s many members, donors, partners and other stakeholders who work so hard to improve the quality of life for people with eczema.